Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289374 | 0.80 | FDPS (0.34) | FDPSMMP1MMP2MMP3MMP8 | |
| SCHEMBL6088197 | 0.80 | FDPS (0.34) | FDPSMMP1MMP2MMP3MMP8 | |
| SCHEMBL181792 | 0.65 | — | — | |
| SCHEMBL2961086 | 0.65 | — | — | |
| SCHEMBL3064325 | 0.65 | LMNA (0.40) | FDPSLMNAGRM4 | |
| SCHEMBL8529847 | 0.65 | FDPS (0.43) | FDPSMMP1MMP2MMP3MMP8 | |
| SCHEMBL13645503 | 0.63 | LMNA (0.39) | FDPSMMP1MMP2MMP3MMP8 | |
| SCHEMBL11408032 | 0.62 | LMNA (0.38) | FDPSMMP1MMP2MMP3MMP8 | |
| Phosphoric Acid SCHEMBL192007 | 0.61 | FDPS (0.46) | FDPSMMP1MMP2MMP3MMP8 | |
| Phosphoric Acid SCHEMBL21359160 | 0.61 | FDPS (0.46) | FDPSMMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889850-B1 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME | POLA CHEM IND INC (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-7718635-B2 | Triterpenic acid derivative and preparation for external application for skin comprising the same | POLA CHEMICAL INDUSTRIES INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090075946-A1 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME | POLA CHEMICAL INDUSTRIES INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1889850-A1 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME | Pola Chemical Industries Inc. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075946-A1 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME | DUSP4, CUTA, DUSP22 | FDPS 1445/4885MMP1 2581/4885MMP2 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.